Beijing Med-Pharm Corp. And Cytokine PharmaSciences Reach Agreement On Development And Commercialization Of Second-Generation Obstetrics Product In China

PLYMOUTH MEETING, Pa. & KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Beijing Med-Pharm Corporation (NASDAQ: BJGP) and Cytokine PharmaSciences, Inc. today announced an agreement under which Beijing Med-Pharm will conduct late-stage clinical development, registration, sales, marketing and distribution in the People’s Republic of China of Cytokine’s Misopess™, a second-generation vaginal insert under investigation in several countries for cervical ripening and induction of labor.

Back to news